drugset / Trial / NCT01397838
Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
NaSingle-groupOpen-labelPrevention
Summary
Recent studies have shown that inhibition of Aquaporine-9 channels may ameliorate the bone degradation process. Pro-bone is an AQ - 9 channels inhibitor. This study is design to evaluate the safety of Pro-bone.
Timeline
- Start
- 2011-09
- Primary completion
- 2011-12
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pro-Bone | Unknown | 500 mg | Oral |